SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company with a current market capitalization of ...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at $1.70 per share, expecting to raise $10 million ...
HeartBeam system was recently cleared by the U.S. Food and Drug Administration (FDA) for comprehensive arrhythmia assessment 510(k) application submitted to the FDA for the Company’s ...
SANTA CLARA, Calif., February 13, 2025--HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock As the U.S. stock market navigates a mixed landscape of earnings ...
HeartBeam, Inc, a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today ...
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment The Company is gearing up for an Early Access Program to gain initial ...
Despite a net loss and cash constraints, HeartBeam Inc (BEAT) remains optimistic about FDA clearance and its groundbreaking ECG technology. As the U.S. stock market experiences a downturn ...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that it has priced its public ...
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/106.BfLtBoPo.js ...